Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -20.56% is 32% below its 5-year average of -15.53%, around the middle of its 5-year range (-101.68%–43.14%).
7.19% below its 12-month average of -19.18%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-03-31): -17.21%.
NET PROFIT MARGIN
-20.56%
NET PROFIT MARGIN AVG TTM
-19.18%
NET PROFIT MARGIN AVG 3Y
-22.76%
NET PROFIT MARGIN AVG 5Y
-15.53%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-7.19%
CURRENT VS 3Y AVG
+9.67%
CURRENT VS 5Y AVG
-32.41%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-7807.69%
vs the sector median at left
Universe Pharmaceuticals Inc.
Market Cap
$2.65M
Net Profit Margin
-20.56%
TTM Avg
-19.18%
3Y Avg
-22.76%
5Y Avg
-15.53%
Market Cap
$2.69M
Net Profit Margin
-2449.04%
TTM Avg
-339.09%
3Y Avg
-222.12%
5Y Avg
-170.97%
Market Cap
$2.56M
Net Profit Margin
-123.38%
TTM Avg
-169.81%
3Y Avg
-184.41%
5Y Avg
-199.55%
Market Cap
$2.54M
Net Profit Margin
-257.33%
TTM Avg
-169.26%
3Y Avg
-42605.81%
5Y Avg
-28403.87%
Market Cap
$2.44M
Net Profit Margin
-131.76%
TTM Avg
-396.75%
3Y Avg
-403.38%
5Y Avg
-531.17%
Market Cap
$2.38M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$2.38M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$2.37M
Net Profit Margin
-1578.79%
TTM Avg
-2023.10%
3Y Avg
-17008.17%
5Y Avg
-11338.78%
Market Cap
$2.37M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Universe Pharmaceuticals Inc. (UPC) | $2.65M | -20.56% | -19.18% | -22.76% | -15.53% |
| iSpecimen Inc. (ISPC)vs › | $2.69M | -2449.04% | -339.09% | -222.12% | -170.97% |
| Nuwellis, Inc. (NUWE)vs › | $2.56M | -123.38% | -169.81% | -184.41% | -199.55% |
| bioAffinity Technologies, Inc. (BIAF)vs › | $2.54M | -257.33% | -169.26% | -42605.81% | -28403.87% |
| Jaguar Health, Inc. (JAGX)vs › | $2.44M | -131.76% | -396.75% | -403.38% | -531.17% |
| Moleculin Biotech, Inc. (MBRX)vs › | $2.38M | 0.00% | 0.00% | 0.00% | 0.00% |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH)vs › | $2.38M | 0.00% | 0.00% | 0.00% | 0.00% |
| Onconetix, Inc. (ONCO)vs › | $2.37M | -1578.79% | -2023.10% | -17008.17% | -11338.78% |
| FibroBiologics, Inc. Common Stock (FBLG)vs › | $2.37M | 0.00% | 0.00% | 0.00% | 0.00% |
| IceCure Medical Ltd (ICCM)vs › | $2.93M | -427.67% | -455.53% | -478.79% | -375.12% |
Operating Margin
-16.3%
Net Profit Margin
-20.6%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-03-31 | -17.21% |
| 2025-09-30 | -4.45% |
| 2025-03-31 | -35.89% |
| 2024-09-30 | 43.14% |
| 2024-03-31 | -101.68% |
| 2023-09-30 | -39.36% |
| 2023-03-31 | -3.87% |
| 2022-09-30 | -65.67% |
| 2022-03-31 | 7.16% |
| 2021-09-30 | 17.61% |
| 2021-03-31 | 29.42% |
| 2020-09-30 | 24.62% |
| 2020-03-31 | 24.62% |
| 2019-09-30 | 22.73% |
| 2019-03-31 | 22.73% |
| 2018-09-30 | 26.66% |
| 2018-03-31 | 26.66% |
